The newly cleared device is designed to divert blood flow from aneurysms to promote healing and reduce the risk of rupture, the company said. The Bravo is Cerenovus’ first flow diverter device, the company added.
“Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms. I believe the design of the Bravo flow diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms,” Bravo flow diverter evaluator Dr. Patrick Brouwer of Karolinska University Hospital said in a prepared statement.
“The Bravo flow diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke. Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke,” Cerenovus worldwide prez Daniella Cramp said in a press release.
In May, Cerenovus said that it won FDA 510(k) clearance for the Embotrap II revascularization device.